Oramed

Quick links to important sections

Oramed

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oramed

Oramed: Identity, Active Ingredient, and Class

Property Description
Active ingredient Benzocaine (Ethyl aminobenzoate)
Form Oral spray (solution, aerosol)
Pharmacological class Topical Local Anesthetic
Common use Temporary relief of oral/pharyngeal discomfort
Origin Synthetic

Oramed is a pharmaceutical preparation, typically delivered as an oral spray solution, distinguished by its sole active ingredient, Benzocaine (Ethyl aminobenzoate). The medicine belongs to the pharmacological class of topical local anesthetics, which are compounds designed to induce a reversible loss of sensation in a confined area, a mechanism clinically recognized for managing localized surface pain. Benzocaine is categorized specifically as an ester-type anesthetic, a synthetic compound that acts directly on the tissue surface.

Oramed is positioned for the temporary management of surface discomfort, focusing its delivery system on efficiency for general adult patient groups. The formulation is a monosemantic product, relying entirely on this single active agent, dissolved in a hydroalcoholic base to ensure rapid dispersal and contact with the sensitive mucous membranes of the mouth and throat.


Benzocaine's General Purpose and Form

The general purpose of Oramed is to provide immediate, localized mitigation of surface pain and discomfort, such as soreness or irritation, within the oropharyngeal area. The medicine functions by creating a rapid sensory blockade that prevents localized nerve endings from transmitting pain signals. Topical anesthetics like Benzocaine are utilized for mitigating pain in the oral cavity and throat. This medicine is effective for quickly easing pain on the surface of your mouth and throat.

The choice of an oral spray dosage form is essential to its function, as it allows the Benzocaine-containing solution to be efficiently and precisely applied to the affected tissue linings. This targeted delivery method ensures the anesthetic effect is highly localized and temporary, focusing the mechanism of action directly where the discomfort originates and providing a direct functional benefit by alleviating the sensation of surface pain.

What side effects are possible with Oramed?

The official regulatory safety profile for Oramed, which contains the active ingredient Benzocaine, is structured around documented adverse events, their severity classifications, and specific limitations concerning patient populations.

Serious Adverse Reactions and Systemic Risk

The most critical safety feature documented in official labeling is the potential for Methemoglobinemia. This is a serious blood disorder that impairs the blood's ability to carry oxygen and is classified as a rare event, though regulatory authorities require explicit warnings due to its potentially fatal nature. Manifestations are often systemic, including changes in skin color, dizziness, and rapid heart rate, typically classified as incidence not known.

Localized and General Adverse Reactions

The most commonly reported adverse reactions are associated with the application site, classified under Skin and subcutaneous tissue disorders and General disorders and administration site conditions. These effects include localized burning, stinging, redness (erythema), and itching (pruritis). Allergic and hypersensitivity reactions are also documented, classified under Immune system disorders.

Population-Specific Safety Constraints

The medicine is explicitly contraindicated for use in children younger than 2 years of age due to the heightened risk of Methemoglobinemia. Official documents also identify older adults and patients with certain predisposing medical conditions (such as heart or breathing problems) as being at an increased risk for this serious adverse reaction. Additionally, use is restricted in individuals with a known sensitivity to Benzocaine or other ester-type local anesthetics.

Overdose and Emergency Response

An overdose of Oramed, like any agent that affects blood sugar, carries the primary risk of inducing hypoglycemia (dangerously low blood sugar). Because the drug works to lower glucose levels, taking more than the prescribed amount can cause a significant drop in blood glucose that may progress from mild to severe, requiring immediate medical intervention.

Recognizing Hypoglycemia

Symptoms of low blood sugar are categorized by severity and can differ among individuals. Early recognition is crucial to prevent progression to a medical emergency.

Symptom Severity Common Manifestations
Mild Trembling, sweating, anxiety, rapid heartbeat, extreme hunger, dizziness, headache
Severe Confusion, disorientation, slurred speech, seizures, loss of consciousness, coma

When to Seek Immediate Help

If you or someone else has taken an overdose of this medication, seek emergency medical care immediately. Do not wait for symptoms to worsen. Call emergency services right away if the individual:

  • Exhibits severe symptoms such as confusion, difficulty speaking, or a seizure.
  • Becomes unresponsive or loses consciousness.
  • Is awake but unable to swallow food or drink safely to raise blood sugar.

Immediate medical assessment and supportive care, including the administration of glucose, are essential to reverse severe hypoglycemia and prevent potential permanent neurological injury or death.

Therapeutic Uses of Oramed

Oramed is aligned with therapeutic domains focused on providing localized symptomatic support for the mouth and throat. It is generally used for the temporary relief of pain due to minor irritation, soreness, or injury of the mouth and throat. It is relevant for managing symptoms that interfere with daily comfort.

The medicine is commonly used across conditions characterized by episodic or fluctuating symptom patterns, including generalized minor sore throat, localized discomfort from canker sores or small abrasions to the gum tissue, and functional strain during the adjustment phase of dental appliances. This medicine is relevant when supportive symptom management is appropriate for temporary symptoms related to physical discomfort in the oropharyngeal area.

Relief for Minor Oropharyngeal Soreness and Irritation

This domain covers acute, surface-level pain and irritation within the pharynx and oral cavity, such as general soreness or scratchiness in the throat. Providing supportive relief, Oramed contributes to easing the overall symptom load related to inflammatory or irritative states.

Management of Localized Pain from Oral Lesions

Oramed is applicable in situations where symptom clusters require management of pain originating from specific focal points. It helps address these painful symptoms that may appear suddenly, provides support that helps ease the overall symptom burden during periods of heightened symptoms.

Quick Fact: Relief for Localized Oral Discomfort Oramed is commonly used for conditions presenting with systemic or localized discomfort, may assist with maintaining functional stability when symptoms become more noticeable, particularly during the acute phases of minor oral lesions.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Oramed — official regulatory information


Eligibility Scope

Category Regulatory Status Description
Populations Allowed Permitted Use Adults and children 2 years of age and older are eligible for use.
Populations Contraindicated Absolute Prohibition Infants and children younger than 2 years must not use this medicine.

Age-Related Eligibility and Prohibitions

Official regulatory documents define a contraindication for all use in patients younger than two years of age, including use for teething pain. The standard labeled use is established only for adults and children two years of age and older. Older adult patients are recognized as a population at greater risk for complications and may require special consideration.

Condition-Specific Eligibility Rules

This medicine is restricted for use in patients with certain pre-existing conditions. Contraindications include a known history of methemoglobinemia or a known allergy to benzocaine (or other ester-type anesthetics). Caution is required for individuals with heart disease, lung or breathing problems (e.g., asthma, emphysema), or hereditary metabolic disorders (e.g., G6PD deficiency).

Pregnancy and Lactation Eligibility Status

This medicine is classified as FDA Pregnancy Category C, indicating that use is contingent on a risk-benefit assessment. During lactation, the regulatory position recommends caution and advises against application to the breast or nipple to prevent potential ingestion by the infant.


Connection to the overall eligibility profile: The regulatory documents define who can and cannot use this medicine by establishing a strict age-based floor and enforcing absolute prohibitions based on hypersensitivity or underlying hematologic and cardiopulmonary conditions. These explicit eligibility constraints focus on minimizing documented physiological risks, thereby restricting standard use to patients aged two years and above who do not have the identified contraindicating or high-risk comorbidities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Interaction Statements

The interaction profile of Oramed (Benzocaine) is primarily structured around a pharmacodynamic interaction that results in an additive risk of methemoglobin formation.

Officially documented statements based on regulatory data describe several interacting substance categories:

  • Other Local Anesthetics: Co-administration with other local anesthetic agents, such as lidocaine or prilocaine, is noted to result in an additive toxicological effect and an increased potential for methemoglobinemia.
  • Methemoglobin-Inducing Agents: Simultaneous use with medicinal products that induce methemoglobin formation, including certain nitrate derivatives (e.g., nitroglycerin, nitroprusside) and Dapsone, leads to an additive risk of methemoglobin formation.
  • Non-Medicinal Substances: The risk of methemoglobin formation is also documented as being additive when Oramed is used concurrently with foods and water containing nitrites and nitrates.

Population-Specific Interaction Notes

The official labeling includes cautions that the sensitivity to this additive interaction is heightened in certain populations. The risk of complications related to methemoglobinemia is documented as being greater for elderly patients and individuals with pre-existing conditions such as heart disease or breathing problems (e.g., asthma, COPD). The severity of the additive risk warrants consideration in these specific patient groups.

Mechanism of Action

Mechanism of Action

Mechanism of Intestinal Absorption and Systemic Delivery

Oramed's mechanism addresses biological factors limiting oral drug delivery. The specialized capsule is designed to protect the active compound from breakdown by gastric acid and digestive enzymes, promoting its passage to the small intestine in an intact state. This is facilitated by a combination of absorption enhancers and protease inhibitors, which transiently and locally modify intestinal epithelial permeability. This allows the active compound to enter the portal circulation for subsequent hepatic targeting.


Influencing Hepatic Pathway Regulation

Once absorbed, the active compound is delivered directly to the liver, which regulates glucose flux. This concentrated delivery confers an effect focused on the hepatic pathway. Here, the compound modulates key enzymes and signaling cascades involved in endogenous glucose production (EGP) and release. This pathway engagement influences hepatic glucose regulation by altering the balance of cellular processes that control glucose output.

Dosage and Administration Information

How to Use Oramed

Oramed is administered strictly through topical application to the mucous membranes of the mouth and throat via an oral spray. This method is designed to facilitate localized action within the specified dosing limits. The medicine is used on an as-needed (P.R.N.) basis for temporary symptom relief, not as a continuous scheduled therapy.


Official Administration Guidelines

Guideline Entity Official Instruction
Route & Method Topical application to the oropharyngeal area using an oral aerosol spray.
Standard Dosing Apply one to four actuations (sprays) to the affected localized area. Use is limited to a maximum of four times daily.
Timing & Food Consumption of food or liquids must be avoided for at least one hour after using the spray to maintain the localized effect.
Duration Constraint Use is limited to short-term relief and should not exceed 7 days.
Age Restriction The product must not be used in children younger than two years of age.

Procedural Summary

Administration involves directing the prescribed number of actuations (typically 1–4) onto the specific area of discomfort, such as the back of the throat or the mucous lining. The maximum frequency is constrained to prevent overuse, and the medicine is designated for episodic pain management only, not for long-term conditions. Following the application, the required waiting period before intake of food or drink ensures the anesthetic agent remains localized on the surface tissue.

Recent Clinical Evidence

Research evidence / Overview of studies for Oramed

Evidence for use in Type 2 Diabetes Mellitus

Research was studied for how it might relate to conditions characterized by fluctuating or episodic manifestations of blood sugar levels. Scientists research examined how blood sugar markers changed in adults with Type 2 Diabetes Mellitus (T2DM) during short-term, controlled studies, often comparing it to a dummy pill (placebo). These studies explored outcomes related to systemic or functional imbalance, such as measures of average blood sugar (like HbA1c) and glucose levels taken after fasting. The findings describe patterns observed in the studies where some trials described measured changes in these blood sugar markers during the study period among participants receiving the study agent. The follow-up durations were limited in many of these initial comparisons.

Evidence for use in Type 1 Diabetes Mellitus

The agent was evaluated in a separate set of smaller, early-stage studies for its use in patients with Type 1 Diabetes Mellitus (T1DM), which are conditions presenting with cycles of stability and flare-ups. This research was studied for its potential to relate to the body’s natural insulin production and sensitivity. The initial research studies report how symptoms evolved in the observed populations and findings describe patterns observed in the studies relating to these physiological markers. Evidence is limited and remains mostly confined to early-phase research.

Evidence in Non-Alcoholic Steatohepatitis (NASH)

The agent was observed in a limited number of studies that focused on patients who had T2DM along with Non-Alcoholic Steatohepatitis (NASH), a form of fatty liver disease. These studies explored outcomes linked to inflammatory or irritative states in the liver, such as specific blood tests and imaging markers. The findings describe patterns observed in the studies where research reported measurements related to the various outcomes for liver health. Evidence is limited for these patients, and comparative evidence is lacking against other approaches used for NASH management.

What is still uncertain about the research

A key area of uncertainty is the lack of information on long-term effects, as long-term outcomes are not fully established. Additionally, comparative evidence is lacking from studies directly comparing the agent to a full range of other established options. Data for certain groups remain insufficient, and subgroup findings are uncertain for specific populations, such as younger patients or older adults. The current research provides context but not individual predictions, and the available evidence highlights what is known — and what is still uncertain.

Key Studies & References

  1. Efficacy and safety of 28‐day treatment with oral insulin (ORMD‐0801) in patients with type 2 diabetes mellitus
  2. Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate

Frequently Asked Questions (FAQ)

Common questions about Oramed (FAQ)

Q: Why is Oramed considered an 'oral' medication?

Official documents describe Oramed's administration as a topical application to the mucous membranes of the mouth and throat. It is referred to as 'oral' because the spray solution is applied directly to the oropharyngeal area, consistent with the labeled route of use.


Q: Will Oramed interact with my blood pressure medication?

Regulatory documents specify an increased risk of a serious blood condition called methemoglobinemia when Oramed is used concurrently with medicines that induce this effect. This includes certain types of blood pressure or heart medications, such as nitrate derivatives like nitroglycerin.


Q: Is Oramed appropriate for people over the age of 65?

Official documents state that adults, including older adults, are eligible to use this medicine. However, they are also recognized as a patient group at greater risk for complications related to a rare but serious blood condition called methemoglobinemia.


Q: Are there any long-term studies on the use of Oramed?

The official usage guidelines state that use is limited to short-term relief, typically not exceeding seven days. Consistent with this, the research overview indicates that long-term outcomes and effects of the agent are not fully established in studies.


Q: Do I need to change my diet while taking Oramed?

Official guidelines indicate a constraint that consumption of food or liquids is to be avoided for at least one hour after applying the spray. Additionally, regulatory documents warn about a potential additive risk of complications when used concurrently with foods and water containing nitrites and nitrates.


Q: What research is currently underway for Oramed?

Studies and official information review the agent's relationship to conditions such as Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus, and Non-Alcoholic Steatohepatitis (NASH). The research themes focus on examining changes in physiological markers associated with these conditions.


Q: Are the side effects of Oramed generally mild?

The most common adverse reactions reported are localized effects at the application site, such as burning or stinging. However, official documents also carry a required warning about the rare, serious, and potentially fatal risk of Methemoglobinemia, a blood disorder.


Q: How does Oramed fit into a daily routine?

Official documentation defines the use of Oramed as as-needed (P.R.N.) for temporary symptom relief. The maximum use is constrained to no more than four times daily, fitting into a routine as an episodic pain management tool.


Q: Are there specific food types to avoid while using Oramed?

Official documents advise caution regarding co-administration with foods and water containing nitrites and nitrates. This is due to a documented additive risk of developing methemoglobinemia, a serious blood condition.


Q: Does Oramed work by affecting the liver?

The specialized mechanism described in official texts refers to an active compound delivered directly to the liver. Here, the compound is studied for its ability to influence key enzymes involved in the liver's regulation of endogenous glucose production (EGP).


Q: What does the official documentation say about Oramed’s efficacy?

Research evidence describes that studies examined how blood sugar markers, such as HbA1c and fasting glucose, changed in participants. The findings describe patterns observed in these studies where measured changes in these blood sugar markers were noted during the study period.


Q: Is Oramed approved for all types of relevant conditions?

Official documents designate the product's primary purpose as the temporary relief of oral/pharyngeal discomfort. Separate research studies have also explored the agent's potential application related to systemic conditions such as Type 2 Diabetes Mellitus.


Q: Do the official guidelines mention any specific lifestyle changes with Oramed?

The official guidelines include temporary restrictions on consuming food or liquids for one hour following application. Additionally, warnings exist regarding potential interactions with nitrites and nitrates found in certain foods and water.


Q: Can Oramed cause issues with digestion?

The most commonly reported adverse effects are localized reactions, such as burning and stinging, at the application site. Since the medicine is applied topically to the mouth and throat, its effects are generally concentrated in the oropharyngeal area.


Q: Are there specific patient groups where Oramed has been studied more?

According to the official overview of studies, the research evidence is primarily described in the context of adults with Type 2 Diabetes Mellitus (T2DM). Separate smaller studies have also been conducted in populations with Type 1 Diabetes Mellitus (T1DM) and Non-Alcoholic Steatohepatitis (NASH).


Q: What is the general expectation for people starting Oramed?

The general expectation is for the medicine to provide immediate, localized mitigation of surface pain and discomfort. Official guidelines specify that Oramed is used on an as-needed basis for short-term relief of symptoms.


Q: Is Oramed a type of insulin?

Official documents state that Oramed's active ingredient is Benzocaine, which belongs to the pharmacological class of Topical Local Anesthetics. This class of compounds is designed to manage localized surface pain.


Q: How quickly can a person expect Oramed to start working?

Studies related to the medicine’s active ingredient indicate that the onset of the local anesthetic effect typically occurs rapidly. The sensation-blocking effect is generally observed within approximately 30 seconds of topical application.


Q: Can I take Oramed with common vitamins or supplements?

While official interaction statements focus on other medications, general regulatory cautions advise that individuals discuss the use of this medicine concurrently with other medications or supplements with a healthcare professional.


Q: What happens if I miss a dose of Oramed?

The medicine is designated for as-needed (P.R.N.) use for temporary symptom relief, rather than as a continuous scheduled therapy. For this reason, the concept of 'missing a dose' in a scheduled regimen does not typically apply.


Q: Does Oramed affect weight gain or weight loss?

The authorized use of Oramed is for the temporary relief of oral and throat discomfort. Regulatory agencies have concluded that the evidence is inadequate to establish the effectiveness of the active ingredient for other uses, such as weight control.


Q: Are there any known issues with taking Oramed and alcohol?

General regulatory cautions indicate that discussion about the concurrent use of this medicine and alcohol may be relevant.


Q: What is the longest period Oramed has been studied in trials?

Official documentation states that the research studies have had limited follow-up durations. The information available emphasizes that outcomes related to the long-term effects of the agent are not fully established in the current evidence.


Q: Does Oramed require a prescription?

The active ingredient, Benzocaine, in its oral product form, is generally classified by regulatory agencies as an Over-the-Counter (OTC) drug.


Q: What kind of tests are needed before starting Oramed?

Official warnings identify specific high-risk groups, such as patients with a history of methemoglobinemia or certain hereditary metabolic disorders like G6PD deficiency. These conditions are associated with a greater risk of complications.


Q: Is Oramed a new drug or has it been around for a while?

The active ingredient in Oramed, Benzocaine, is a synthetic compound belonging to the ester-type anesthetic class. This type of compound has been widely studied for its ability to manage localized surface pain.


Q: What information is available about Oramed's safety classification?

The medicine is classified by the FDA as Pregnancy Category C, meaning use is contingent on a risk-benefit assessment. In its oral form, the product is generally designated as an Over-the-Counter (OTC) medicine with specific regulatory warnings.


Q: What happens if I feel tired after taking Oramed?

Official documents list fatigue or unusual tiredness as a possible symptom of the serious adverse reaction, Methemoglobinemia. This serious but rare blood disorder impairs the blood's ability to carry oxygen.


Q: If I am taking Oramed, can I still take over-the-counter pain relievers?

Official documents warn against co-administration with other substances that induce methemoglobin formation. Some common pain relievers are known to carry this risk, and this potential risk is a factor that is often discussed with a healthcare professional.


Q: What is the maximum duration of effect for a dose of Oramed?

The local anesthetic effect of the active ingredient, which creates a temporary sensory blockade, typically lasts for a short period. The duration of relief is generally observed to be between 5 to 15 minutes per application.


Q: What is the relationship between Oramed and the body's natural processes?

The medicine is classified as a Topical Local Anesthetic that works by creating a rapid sensory blockade. It functions by preventing localized nerve endings in the affected tissue from transmitting pain signals to the brain.

How should Oramed be stored and disposed of?

How to Store and Dispose of Oramed?

Oramed, as a benzocaine oral spray, must be stored and disposed of according to official regulatory requirements, with specific attention paid to its aerosol format.

Requirement Official Rule (Regulatory Labeling)
Temperature & Protection Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F). Keep from freezing. Do not expose to temperatures above 49 C (120 F). Protect from heat, open flame, and direct light.
Container & Handling Keep the container tightly closed. Do not puncture, pierce, or incinerate the pressurized canister, even when empty. Avoid breathing the mist or vapor.
Child Safety Keep out of the sight and reach of children (mandatory warning).
Disposal Dispose of unused or expired medicine in accordance with local, regional, and national regulations. The preferred method is a drug take-back program. Do not flush the product down a toilet or pour it into a drain unless specifically instructed by a regulatory body.

These official rules ensure the safety and stability of the medicine, particularly by managing the risks associated with a pressurized, flammable product, and by defining proper environmental discarding procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oramed found in:

A-Z Index: